Alyeska Investment Group
AGMB

Alyeska Investment Group’s AgomAb Therapeutics NV AGMB Stock Holding History

Alyeska Investment Group’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75,000
Closed -$787K – 843
2026
Q1 		$787K Buy
+75,000
New +$1.06M ﹤0.01% 579

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Alyeska Investment Group's AGMB Position: Q2 2026 in Review

Alyeska Investment Group sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 75,000 shares — an estimated $787K sold.

Alyeska Investment Group first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $787K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • Alyeska Investment Group reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 AgomAb Therapeutics NV shares in Q2 2026, an estimated $787K.
  • Alyeska Investment Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
  • Alyeska Investment Group's AgomAb Therapeutics NV position peaked at $787K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.